Physician profile
Alan R Faulkner
NPI 1043312887
$134,925.52
in general payments reported to CMS, 2019-2025
35 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,720 · 2021: $25K · 2022: $5,409 · 2023: $22K · 2024: $30K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Food and Beverage: $30K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Travel and Lodging: $1,399 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,842.50 |
| Food and Beverage | $30,487.02 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,650.00 |
| Travel and Lodging | $1,399.09 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $39,516.18 | 2021-2025 | Lensar Laser System |
| Bausch & Lomb Americas INC. | $31,137.61 | 2022-2025 | Miebo, Xiidra, Lotemax |
| Alcon Vision LLC | $22,527.94 | 2019-2025 | Wavelight Ex500 Excimer Laser, Wavelight, Wavelight Refractive Suite |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16,404.47 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $5,845.19 | 2021-2022 | |
| Amgen INC. | $5,702.00 | 2024-2025 | Tepezza |
| Omeros Corporation | $3,289.78 | 2019-2021 | |
| Rxsight INC | $1,824.27 | 2021-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Eyevance Pharmaceuticals LLC | $1,525.70 | 2019-2021 | |
| Glaukos Corporation | $1,421.94 | 2021-2025 | Kxl System, Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Eyepoint US, INC. | $1,272.84 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $803.09 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Novartis Pharmaceuticals Corporation | $677.27 | 2019-2023 | |
| Dompe US, INC. | $509.01 | 2021-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $439.04 | 2021-2025 | Tecnis Iol |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $369.79 | 2022-2023 | Tepezza |
| Shire North American Group INC | $234.99 | 2019 | |
| Ivantis, INC | $229.24 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $216.34 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $182.78 | 2022-2024 | Tyrvaya |
| Galderma Laboratories, L.P. | $162.86 | 2019-2023 | |
| Harrow Eye, LLC | $147.61 | 2023-2025 | Iheezo, Vevye, Verkazia |
| Sight Sciences, INC. | $82.99 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Carl Zeiss Meditec, INC. | $80.93 | 2019 | |
| Abbvie INC. | $68.57 | 2022-2024 | |
| Ziemer USA | $48.46 | 2021 | |
| Allergan, INC. | $38.57 | 2021-2022 | |
| Biotissue Holdings INC. | $30.00 | 2025 | |
| Mallinckrodt Hospital Products INC. | $27.18 | 2022 | |
| Kedrion Biopharma, INC. | $24.84 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Beaver-Visitec International, INC. | $24.33 | 2025 | |
| Aerie Pharmaceuticals, INC. | $22.65 | 2021 | |
| Welch Allyn | $19.41 | 2021 | |
| Staar Surgical Company | $17.65 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Faulkner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.